Enzolytics Inc (ENZC)

[falon]

Facts are stubborn things; and whatever may be our wishes, our inclinations, or the dictates of our passion, they cannot alter the state of facts and evidence
John Adams

ENZC is all about potential.

having or showing the capacity to become or develop into something in the future.

The conundrum is can they deliver.

There has been plenty of press releases, magazine articles, tweets, podcasts and other forms of information sharing that strongly suggest that ENZC has substantial potential to contribute significantly to the pharmaceutical arena.

Certainly there has been some confusing messaging while at other times very clear and precise.

We know what the company has shared and don't know much of just how far ENZC has progressed in some of their biotechnology development.

They talked of revolutionizing drug development and disease prevention through the power of AI and monoclonal antibody technology. The also said they created a topical antibody for Covid-19 designed for administration as a nasal spray.
https://www.lifesciencesreview.com/enzolytics

Fully Human Monoclonal Antibody Technology

https://enzolytics.com/proprietary-therapeutics/

With the recent acquisition of the technology created by BioClonetics Immunotherapeutics, Inc., the Company has additional and complementary technology for producing fully human monoclonal antibodies (mAbs) that neutralize the HIV virus. The Company is in the final development of the recombinant of the parent antibody (identified as “Clone 3”), which has been shown in in vitro tests conduction in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 mAb targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of all now known 87,336 HIV isolates analyzed by the Company’s use of artificial intelligence.The failure of other mAbs, such as the Vaccine Research Group VRC01 [Bar KJ, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med. 2016;375(21):2037-50. PMCID|5292134] resulted from the targeting of mutable epitopes of the HIV virus.

ITV-1 immunotherapy treatment is better long term than antiretroviral therapy (ART) and a CURE is highly achievable.

Case for a cure

https://www.thelancet.com/journals/lancet/article/PIIS2352-3018(20)30232-0/fulltext

Access and adherence
ART remains, at the individual level, one of the most effective tools to fight HIV and has shown global success in prolonging life and reducing risk of transmission. Yet ART is limited by several factors that can inhibit long-term retention and drive loss to follow-up. Despite increased access to generics and free services, people living with HIV encounter barriers in accessing ART and related services and adhering to lifelong ART regimens (eg, treatment fatigue, pill burden, side-effects, job and food insecurity, stigmatisation, and health service dissatisfaction). Many LMICs face compounding structural barriers and service delivery inefficiencies such as long clinic and appointment wait times, long distances to treatment centres, and scarce supplies of quality-assured antiretrovirals. Underserved areas and populations in high-income countries also experience social and structural obstacles to accessing otherwise widely available services, shown by the HIV epidemic in the USA and former Soviet Union countries.
Concerns regarding long-term toxicities of ART continue to emerge, such as the potential association between the integrase inhibitor class (the cornerstone of modern treatment) and obesity and neuropsychiatric disorders. Persistent immune activation and inflammation, even among virally suppressed individuals, are predictive of cardiovascular complications, cancers, osteoporosis, renal disease, neurocognitive disorders, and depression. Drug resistance can arise from poor ART adherence and suboptimal viral suppression rates, driven by weak health systems and treatment interruptions. Although some models suggest life expectancy on optimal ART approaches normal, ART initiation late in disease course and suboptimal adherence are still common. Even when individuals can freely access and remain durably suppressed on ART, life expectancy in many HIV-positive populations in high-income countries is nearly 10 years less than for age-matched, uninfected individuals. With additional data, risk perception, and adherence might worsen

Recombinant Protein-Based COVID-19 Vaccines Workshop

https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/recombinant-protein-based-covid-19-vaccines-workshop-04272023


Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune

https://www.marketscreener.com/quote/stock/ENZOLYTICS-INC-120792338/news/Enzolytics-Inc-Announces-Expansion-of-Production-of-Its-Monoclonal-Antibody-Therapeutics-and-Marke-42341689/

The Company's primary anti-HIV monoclonal antibody has been produced and successfully tested in vitro against multiple strains of the virus where it demonstrated complete efficacy. The recombinant form of the parent antibody has been successfully produced for the Company by Samsung Biologics. This recombinant antibody is currently undergoing efficacy testing in Europe and has shown significant activity even against drug-resistant HIV strains. Studies have confirmed the dual tropic activity of the HIV monoclonal Antibody-Clone 3. For HIV to be infectious, there is a requirement of specific binding between the virus envelope protein and the human CD4 cell at two receptor sites on the CD4 cell and the chemokine co-receptors CXCR4 and/or CCR5. The Company's Clone 3 Antibody interrupts the binding of the virus transmembrane gp41 to the human CD4 cells via blocking of binding to the 2nd co-receptor-to both the CCR5 and the CXCR4 receptors-on the CD4 cell surface. Because Clone 3 is dual-tropic, it consequently prevents HIV infection by abrogating the essential infectivity process which requires the fusion between the viral membrane and the CD4 cell membrane. The success of an anti-HIV monoclonal antibody would be significant.

From the 10Q:

https://www.otcmarkets.com/otcapi/company/financial-report/371665/content

The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody (identified as “Clone 3”) which has been shown in in vitro tests conducted in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 antibody targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of the 87,336 HIV isolates now known which have been analyzed by the Company using Artificial Intelligence (AI).

While the Company’s HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS, they may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current antiretroviral therapy for several significant reasons:

(1) the therapy will be non-toxic (without damage to the kidneys and liver) and will not cause bone density deterioration (osteopenia and osteoporosis) – as does antiretroviral treatments

(2) will not require lifetime treatment

(3) will be far less expensive.

IMHO we will see MASSIVE mAbs update sooner than later.

ENZC has been very busy in the laboratory these past few years.

Charles is in charge!!!

Tell them what you are going to do.

Do it

Tell what you done.

There will be more unbelievable BLOCKBUSTER news to come.

Probably something in the Monoclonal Antibodies area as they have been working with different companies to get the product to the marketplace.
While it is a long process the foundation is set with Samsung and Abveris, a division of Twist Bioscience Corporation as partners.


COLLEGE STATION, TX / ACCESSWIRE / December 19, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).

The Company CEO, Charles Cotropia, said, "Enzolytics is focused on accelerating the growth of our clinical products, technology platforms, and multiple applications now in progress. The Company is making substantial advancement in its three synergistic therapeutic platforms generating multiple clinical products for human and veterinary use. Over the last two years, we have focused on advancing our research and development and strengthening our Intellectual Property portfolio covering our technologies. As a result, we have made significant strides and substantive progress on multiple fronts. Our completion of a two-year audit is just one of the many objectives we have set and achieved.

"In the year ahead, Enzolytics will share additional plans regarding our technologies, planned partnerships, and projects, as well as achievements in each of our therapeutics platforms. We have full faith in our long-term vision and mission and are confident in our team's ability to achieve set goals."

Yep Charles Cotropia dotted the I and crossing the T has brought this company a long way.


NOBODY knows the WHOLE story but the company.

Will the company deliver the goods?

What will the results be?

We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon achievement of defined milestones.

https://www.biospace.com/article/releases/enzolytics-reports-progress-on-its-multiple-therapeutics-platforms-and-initiatives/

Have those milestones be met?

"In the year ahead, Enzolytics will share additional plans regarding our technologies, planned partnerships, and projects, as well as achievements in each of our therapeutics platforms. We have full faith in our long-term vision and mission and are confident in our team's ability to achieve set goals."

https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/12620871/enzolytics-inc-announces-the-completion-of-the-2020-and-2021-audited-financials/

To accelerate and fully execute in the successful production of the multiple monoclonal antibodies the subject of the Company's intellectual property (specifically the numerous monoclonal antibodies (mAbs) targeting both human and animal viruses), the Company continuously engages with numerous entities to accomplish the successful goal of production, testing and delivery of successful therapeutics. Entities with whom the Company is working includes companies having:

Expertise in providing specialized peptides having precise amino acid sequences corresponding to the precise target sites on both the Coronavirus and HIV viruses which are then used in the Company's Texas lab against which mAbs are being produced. This strategy accelerates the production of the mAbs for further development.

Specialized cell soring technology that is complementary to the process used in the Company's lab to accelerate production of mAbs for advancing production.

Expertise in hybridoma production techniques for production of mAbs using hybridoma methodologies that are complementary to the process used in the Company's lab.

Animal trials centers, both in the U.S. and abroad, for preparation of animal trials.

Promotional entities with specialized expertise in targeting large funding sources for the purpose of raising the substantial funds needed for the production of the recombinant mAbs necessary for future trials and for conducting animal trials.

As to each of these entities, and those with whom the Company currently works on an ongoing basis, the Company has entered into NDA's (Nondisclosure Agreements) necessary to preserve and protect the intellectual property being discussed and exchanged between the parties. These contractual restrictions are critical for the Company and its partners. Maintenance of strict confidentiality is absolutely essential to preserving intellectual property rights (patent rights) which are now being sought and which will be sought in the future. Premature disclose of technical information may and generally does bar the right to successfully seek patent protection at a later date. The Company is not able to share specific information regarding arrangements regarding these NDA's

https://www.yahoo.com/now/enzolytics-announces-international-patent-office-103000840.html


5 REASONS WHY ENZOLYTICS IS A COMPELLING CHOICE!
https://www.aviseanalytics.com/5-reasons-why-enzolytics-inc-is-a-compelling-choice/



What are all of the substantial POTENTIAL that my rise out of ENZC:

1. The Price

2. Africa ITV-1 treatment

3. Samsung Biologics Website: https://samsungbiologics.com/en

4. Scendea USA, Inc. (www.scendea.com)

5. IPF Immune(TM)

6. SPAC deal with SAGA

7. Abveris, a division of Twist Bioscience Corporation https://www.abveris.com/

8. Effectiveness of ITV-1 immunotherapy on Diabetes.

9. Dividend

10. Development of Feline Leukemia Monoclonal Antibodies

11. Clone 3

12. Production Monoclonal Antibodies against HIV

13. Development Monoclonal Antibodies against the Corona Virus

14. Patents

15. AI

16. Advancing multiple therapeutics targeting numerous infectious diseases

17. Much more yet to be revealed

ENZC does not release PRs with the expectation of a stock price rise, they release PRs to share information with their shareholders.


PRESS RELEASES do not rise up stock prices certain RESULTS does.

The most successful men in the end are those whose success is the result of steady accretion.
Alexander Graham Bell

AIMHO